Clinical Trials Logo

Filter by:
NCT ID: NCT02473965 Completed - Myasthenia Gravis Clinical Trials

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Start date: June 2015
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG).

NCT ID: NCT02473952 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.

NCT ID: NCT02465814 Completed - Leiomyoma Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

ASTEROID 2
Start date: June 2015
Phase: Phase 2
Study type: Interventional

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.

NCT ID: NCT02453256 Completed - Systemic Sclerosis Clinical Trials

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

focuSSced
Start date: November 20, 2015
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

NCT ID: NCT02447302 Completed - Ulcerative Colitis Clinical Trials

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Start date: October 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.

NCT ID: NCT02446899 Completed - Clinical trials for Active Systemic Lupus Erythematosus

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Start date: July 9, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

NCT ID: NCT02436655 Completed - Aortic Stenosis Clinical Trials

Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis

AVATAR
Start date: June 2015
Phase: N/A
Study type: Interventional

Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left ventricular ejection fraction remains controversial. The investigators therefore try to compare clinical outcomes of elective aortic valve replacement to conventional treatment and watchful waiting strategy in a prospective randomized trial.

NCT ID: NCT02425644 Completed - Multiple Sclerosis Clinical Trials

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

OPTIMUM
Start date: June 4, 2015
Phase: Phase 3
Study type: Interventional

International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis

NCT ID: NCT02423369 Completed - Clinical trials for Newborn, Infant, Disease

Cerebral Oxymetry and Neuronal Markers in Newborns and Infants Undergoing Surgery

NEMARKO
Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether peri-operative period in neonates and infants is associated with an increase in blood biomarkers, specific for neuronal injury, and to correlate them with clinical variables and sedative/analgesic agents. Patients, who meet inclusion criteria and does not meet exclusion criteria, are enrolled. Blood samples for measurement serum concentrations of markers (S100-B and Neuron-Specific Enolase (NSE)) are drawn before surgery (baseline) and on the 1-st, 2-nd and 3-rd day after surgery. During surgery cerebral oxygenation (rSO2) monitoring is continuously applied; rSO2, hemodynamic and respiratory values are simultaneously recorded every 5 minutes. Anesthesia, pre and postoperative treatment, including analgesia and sedation, are given as per standard of care.

NCT ID: NCT02422186 Completed - Clinical trials for Depressive Disorder, Treatment-Resistant

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

TRANSFORM-3
Start date: August 20, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.